- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00122603
Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this randomized, open-label study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease inhibitor naive HIV-1 patients.
Patients with CD4 cell counts over or equal to 200/mm3, HIV viral load between 10,000 and 750,000 copies per milliliter, and wild-type genotype at baseline will be eligible. This multicenter study will enroll 60 patients (n=30 in each group). The planned duration of the study is 48 weeks from the enrolment of the last subject.
The primary efficacy endpoint will be virologic success defined as HIV RNA levels below 50 copies/ml after 16 weeks of initial treatment. The durability of this response will be evaluated and patients will be followed for 48 weeks.
The primary safety endpoint will be treatment interruptions because of adverse effects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75018
- Service des Maladies infectieuses et tropicales Hopital Bichat Claude Bernard
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Protease inhibitor naive patients
- Wild type genotype
- CD4 greater than 200/mm3
- Viral load between 10,000 copies/ml and 750,000 copies/ml
- Signed informed consent
Exclusion Criteria:
- Pregnancy; breast feeding
- Antiretroviral (ARV) pretreated patients
- Hyperlipidemic treatment
- Evolutive disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Atazanavir + Fosamprenavir + ritonavir
|
ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
|
Experimental: group 2
Atazanavir + saquinavir + ritonavir
|
ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Virologic success defined as HIV RNA levels below 50 copies/ml after 16 weeks of initial treatment
|
Secondary Outcome Measures
Outcome Measure |
---|
Body mass index (BMI)
|
Safety of protease inhibitors
|
Percentage of patients with viral load below 400 copies/ml at week 16 (W16)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roland Landman, MD, Hopital Bichat SMIT A Paris
- Study Chair: Jean Pierre Aboulker, MD, Inserm SC10
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Fosamprenavir
- Saquinavir
Other Study ID Numbers
- 2005-003470-20
- ANRS 127 2 IP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Fosamprenavir
-
GlaxoSmithKlineTerminatedHIV-1Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
-
GlaxoSmithKlineCompletedHIV Infection | Infection, Human Immunodeficiency VirusUnited States, Puerto Rico
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcarePfizerTerminated
-
ViiV HealthcarePfizerCompleted
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV-1 Infection | Infection, Human Immunodeficiency Virus IGermany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States, Spain, France, United Kingdom, Chile, Brazil, Italy, Portugal
-
Emory UniversityCompletedHIV InfectionsUnited States
-
Tibotec BVBACompleted
-
ViiV HealthcareCompletedHIV InfectionUnited States, Spain, Portugal, Italy, Romania, Canada, Netherlands